The findings of the Stanford University School of Medicine researchers and external collaborators, in a paper published online on 6 July in the journal Proceedings of the National Academy of Sciences, addressed the possibility that many of us have antibodies in the blood that might be a roll in the ward or slowing the progression of Alzheimer’s disease. This appears to be true , even if we are young and healthy and probably have little or no exposure to the substances that build up in the brain to cause this disorder.
The methods the researchers used, for which Stanford has filed provisional patent applications, could result in better monitoring of clinical trials of immunotherapeutic treatments for Alzheimer’s disease, said Wyss-Coray. ‘With our microarray, you could easily look for antibodies to hundreds of different peptides. It would be possible to see whether certain types of antibodies correlate better with cognitive benefits than others do. ‘., secures, and Capital Fund Backs Stem Cell innovator, UK – PlastiCell assures 690,000 Inclusive Getting Institutional Investment?